黄佳欢^1;2;3;雷蕾^2;3;王晓稼^2;3

• 1:浙江中医药大学第二临床医学院，浙江 杭州 310053
• 2:中国科学院大学附属肿瘤医院(浙江省肿瘤医院)乳腺肿瘤内科，浙江 杭州 310022
• 3:中国科学院基础医学与肿瘤研究所，浙江 杭州 310022

摘要(Abstract)：

乳腺癌是女性最常见的恶性肿瘤，严重威胁着女性健康。紫杉类药物是晚期乳腺癌最常用的化疗药物。白蛋白结合型紫杉醇是一种以纳米微粒白蛋白为载体的新型紫杉烷类制剂，对晚期乳腺癌的治疗取得显著疗效。本文对药物的抗肿瘤机制以及白蛋白结合型紫杉醇单药或联合用药治疗晚期乳腺癌的相关临床研究作一综述，寻找更为安全有效且个体化的临床治疗方案。

关键词(KeyWords)： 晚期乳腺癌;白蛋白结合型紫杉醇;化疗

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金（81672597）；吴阶平医学基金（320.6750.16226）

作者(Authors): 黄佳欢^1;2;3;雷蕾^2;3;王晓稼^2;3

DOI: 10.13267/j.cnki.syzlzz.2021.099

参考文献(References)：

• [1] Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer prevention[J]. Nat Rev Cancer, 2020, 20(8):417-436.
  [2] Zhao Y, Xu G, Guo X, et al. Early death incidence and prediction in stage Ⅳ breast cancer[J]. Med Sci Monit, 2020, 26:e924858.
  [3] Abu Samaan TM, Samec M, Liskova A, et al. Paclitaxel's mechanistic and clinical effects on breast cancer[J]. Biomolecules, 2019, 9(12):789.
  [4] Palumbo R, Sottotetti F, Trifirò G, et al. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients:prospective evaluation of activity, safety, and quality of life[J]. Drug Des Devel Ther, 2015, 9:2189-2199.
  [5] Gornstein E, Schwarz TL. The paradox of paclitaxel neurotoxicity:Mechanisms and unanswered questions[J]. Neuropharmacology, 2014, 76(Pt A):175-183.
  [6] Petrelli F, Borgonovo K, Barni S. Targeted delivery for breast cancer therapy:the history of nanoparticle-albumin-bound paclitaxel[J]. Expert Opin Pharmacother, 2010, 11(8):1413-1432.
  [7] Neesse A, Frese KK, Chan DS, et al. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice[J]. Gut, 2014,63(6):974-983.
  [8] Gradishar WJ, Tjulandin S, Davidson N, et al. Phase Ⅲ trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer[J]. J Clin Oncol, 2005, 23(31):7794-7803.
  [9] Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer[J]. J Clin Oncol, 2009, 27(22):3611-3619.
  [10] Gradishar WJ, Krasnojon D, Cheporov S, et al. Phase Ⅱ trial of nab-paclitaxel compared with docetaxel as firstline chemotherapy in patients with metastatic breast cancer:final analysis of overall survival[J]. Clin Breast Cancer, 2012, 12(5):313-321.
  [11] O'Shaughnessy J, Gradishar WJ, Bhar P, et al. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors:a retrospective analysis[J]. Breast Cancer Res Treat, 2013,138(3):829-837.
  [12] Fabi A, Giannarelli D, Malaguti P, et al. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer:clinical results and biological observations in taxane-pretreated patients[J]. Drug Des Devel Ther, 2015, 9:6177-6183.
  [13] Tamura K, Inoue K, Masuda N, et al. Randomized phase Ⅱ study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer[J]. Cancer Sci, 2017, 108(5):987-994.
  [14] Luhn P, Chui SY, Hsieh AF, et al. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer[J]. J Comp Eff Res, 2019, 8(14):1173-1185.
  [15] Roy V, LaPlant BR, Gross GG, et al. Phase Ⅱ trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcit-abine in patients with metastatic breast cancer (N0531)[J]. Ann Oncol, 2009, 20(3):449-453.
  [16] Yardley DA, Coleman R, Conte P, et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer:results from the tnAcity trial[J]. Ann Oncol, 2018, 29(8):1763-70.
  [17] Hu X, Wang B, Zhang J, et al. Abraxane plus cisplatin compared with gemcitabine plus cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer (GAP):A multicenter, randomized, open-label, phase Ⅲ trial[J]. Ann Oncol, 2020, 31(S4):S354.
  [18] 陈俊青, 陈占红, 王晓稼. 2018年美国ASCO会议三阴性乳腺癌研究进展[J]. 实用肿瘤杂志, 2018, 33(6):510-514.
  [19] Lobo C, Lopes G, Baez O, et al. Final results of a phase Ⅱ study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer[J]. Breast Cancer Res Treat, 2010, 123(2):427-435.
  [20] Lo SS, Guo R, Czaplicki KL, et al. Abstract P1-12-04:Carboplatin, nab-paclitaxel and bevacizumab as first-line treatment for metastatic breast cancer[J]. Cancer Res, 2012, 72(Suppl 24):P1-12-04.
  [21] Hamilton E, Kimmick G, Hopkins J, et al. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer[J]. Clin Breast Cancer, 2013, 13(6):416-420.
  [22] Mirtsching B, Cosgriff T, Harker G, et al. A phase Ⅱ study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer[J]. Clin Breast Cancer, 2011, 11(2):121-128.
  [23] Rugo HS, Barry WT, Moreno-Aspitia A, et al. Randomized phase Ⅲ trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer:CALGB 40502/NCCTG N063H (Alliance)[J]. J Clin Oncol, 2015, 33(21):2361-2369.
  [24] Oliver PG, LoBuglio AF, Zhou T, et al. Effect of anti-DR5 and chemotherapy on basal-like breast cancer[J]. Breast Cancer Res Treat, 2012, 133(2):417-426.
  [25] Forero-Torres A, Varley KE, Abramson VG, et al. TBCRC 019:A phase Ⅱ trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer[J]. Clin Cancer Res, 2015, 21(12):2722-2729.
  [26] Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018, 379(22):2108-2121.
  [27] Emens LA, Adams S, Barrios CH, et al. IMpassion130:Final OS analysis from the pivotal phase Ⅲ study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer[J]. Ann Oncol, 2020, 31(S6):S1261.
  [28] 胡跃. 2018 SABCS乳腺癌化疗进展[J]. 实用肿瘤杂志, 2019, 34(5):461-465.
  [29] Marschner N, Salat C, Söling U, et al. Final effectiveness and safety results of NABUCCO:Real-world data from a noninterventional, prospective, multicenter study in 697 patients with metastatic breast cancer treated with nab-paclitaxel[J]. Clin Breast Cancer, 2018, 18(6):e1323-1337.
  [30] Mahtani RL, Parisi M, Glück S, et al. Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer:a US community-based real-world analysis[J]. Cancer Manag Res, 2018, 10:249-256.
  [31] Koumarianou A, Makrantonakis P, Zagouri F, et al. ABREAST:a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer[J]. Breast Cancer Res Treat, 2020, 182(1):85-96.